Review Article
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Table 6
Selected clinical
trials of sunitinib. GIST, gastrointestinal
stromal tumor; PFS, progression free survival; OS, overall
survival; PR, partial response; CR, complete response; TTP, time
to progression; m RCC, metastatic renal cell carcinoma; QOL, quality
of life.
| | Malignancy | Regimen | Number of patients | Response rate | Comments |
| | RCC | Interferon vs. Sunitinib
[48] | 750 pts
Previously untreated mRCC | Sunitinib:
Median PFS (11 mo) ORR (31%)
OS (26.4 mo), = 0.051 Interferon:
Median PFS (5 mo) ORR (6%)
OS (21.8 mo) | Sunitinib provides superior
QOL compared with IFN-α in mRCC patients. |
| | GIST | Sunitinib vs. placebo [50] | 312 pts After progression or
intolerance to imatinib | Sunitinib: TTP(6.3 mo)
Placebo: TTP(1.5 month) | Sunitinib significantly
improved TTP with a 67% reduced risk of progression. |
|
|
